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OBJECTIVES This study was designed to compare primary stenting with optimal directional coronary
atherectomy (DCA).
BACKGROUND No previous prospective randomized trial comparing stenting and DCA has been performed.
METHODS One hundred and twenty-two lesions suitable for both Palmaz-Schatz stenting and DCA
were randomly assigned to stent (62 lesions) or DCA (60 lesions) arm. Single or multiple
stents were implanted with high-pressure dilation in the stent arm. Aggressive debulking
using intravascular ultrasound (IVUS) was performed in the DCA arm. Serial quantitative
angiography and IVUS were performed preprocedure, postprocedure and at six months. The
primary end point was restenosis, defined as ^50% diameter stenosis at six months. Clinical
event rates at one year were also assessed.
RESULTS Baseline characteristics were similar. Procedural success was achieved in all lesions. Although
the postprocedural lumen diameter was similar (2.79 vs. 2.90 mm, stent vs. DCA), the
follow-up lumen diameter was significantly smaller (1.89 vs. 2.18 mm; p 5 0.023) in the stent
arm. The IVUS revealed that intimal proliferation was significantly larger in the stent arm
than in the DCA arm (3.1 vs. 1.1 mm2; p , 0.0001), which accounted for the significantly
smaller follow-up lumen area of the stent arm (5.3 vs. 7.0 mm2; p 5 0.030). Restenosis was
significantly lower (32.8% vs. 15.8%; p 5 0.032), and target vessel failure at one year tended
to be lower in the DCA arm (33.9% vs. 18.3%; p 5 0.056).
CONCLUSIONS These results suggest that aggressive DCA may provide superior angiographic and clinical
outcomes to primary stenting. (J Am Coll Cardiol 1999;34:1050–7) © 1999 by the
American College of Cardiology
Recently, the use of stents for percutaneous transluminal
coronary angioplasty has been expanded. In selected pa-
tients, primary implantation of intracoronary stents im-
proves the early and long-term clinical outcomes of angio-
plasty (1,2). However, extension of stent indications to
complex lesions or small vessels produces less favorable
See page 1058
results (3). Directional coronary atherectomy (DCA) was
developed to excise obstructive coronary atheroma. Al-
though two early randomized trials failed to show a signif-
icant benefit of DCA over conventional balloon angioplasty
(4,5), recent clinical trials have shown that “optimal” DCA,
in particular when using intravascular ultrasound (IVUS),
can be performed safely with favorable long-term outcomes
(6–8). A previous retrospective study comparing stent
implantation with DCA found that stenting provided more
favorable long-term results (9). However, there has been no
prospective randomized trial comparing stent implantation
and “optimal” DCA. The objective of the present random-
ized study was to compare angiographic and clinical out-
comes between primary stenting and optimal atherectomy
by “aggressive” DCA using IVUS, and to evaluate the
difference of chronic vessel response as assessed by serial
IVUS study.
METHODS
Study design. The STent versus directional coronary
Atherectomy Randomized Trial (START) was a random-
ized clinical trial comparing primary stenting with “aggres-
sive” DCA technique. Suitable lesions for both stenting and
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DCA were selected by angiography, by the IVUS image,
and by the clinical condition. Exclusion criteria included the
lesion located in the vessel being smaller than 2.8 mm as
assessed by on-line quantitative coronary angiography
(QCA); the lesion having the arc of superficial calcium
greater than 180 degrees as assessed by IVUS; a restenotic
lesion after stenting or DCA; a nonprotected left main
trunk lesion; an aorto-ostial lesion; a bypass graft lesion or
a thrombotic lesion; and the presence of acute myocardial
infarction within the previous one month, stroke within the
previous three months or peripheral vascular disease that
precluded use of a 10F arterial sheath.
Eligible patients were invited to participate in this trial,
and informed consent was obtained under a protocol ap-
proved by our institutional review board. After online QCA
and preprocedural IVUS, patients were randomly assigned
either to the stent arm or the DCA arm groups. The
primary end point of this study was a six-month angio-
graphic restenosis rate (defined as percent diameter stenosis
[DS] ^50%).
Procedure and medication. In the stent arm group, single
or multiple Palmaz-Schatz stents were implanted to fully
cover the lesion according to standard protocols (10,11). No
other type of stent was used. All stents were implanted with
high-pressure adjunct balloon angioplasty to achieve tar-
geted stent expansion, namely a minimal lumen cross-
sectional area (CSA) ^7.5 mm2 as assessed by IVUS.
In the DCA arm group, aggressive debulking was per-
formed using a 7F or 7F graft Simpson Atherocath accord-
ing to IVUS guidance. Balloon pressures were increased
progressively from 10 psi to a maximum 40 psi. Repeated
debulking of the plaque using IVUS was performed accord-
ing to residual percent plaque plus media cross-sectional
area (PA). The aim of residual percent PA was less than
50%. Low-pressure adjunct dilation was performed using a
conventional balloon (balloon:artery ratio of 1 to 1.2) when
necessary, such as in the presence of intimal flap, or oozing
of the contrast.
Administration of ticlopidine combined with aspirin was
commenced after stenting. Administration of aspirin was
continued during the follow-up period in the DCA arm.
Glycoprotein IIb/IIIa antagonist, anticoagulant or antipro-
liferative medications (12,13) were not used in either
groups.
QCA and IVUS. All pre- and postprocedures, and
follow-up angiography and IVUS imaging, were conducted
immediately after administration of 200 mg of intracoronary
nitroglycerin. Angiography was performed so that each
lesion was viewed from at least two angles. Off-line QCA
was conducted utilizing the view revealing the highest
degree of stenosis. Calculations were made using the Car-
diovascular Measurement System (CMS-MEDIS, Medical
Imaging Systems) by an isolated operator who was blinded
to the patient’s group assignment. The lesion length, refer-
ence diameter, minimal lumen diameter (MLD) and DS
were calculated. Acute gain was defined as the difference
between pre- and postprocedural MLD, and late loss was
defined as the difference between postprocedural and
follow-up MLD. The loss index was calculated as late loss
divided by acute gain.
The IVUS studies were performed using a CVIS Insight
ultrasonographer incorporating a single-element, 30-MHz
beveled transducer within a 3.2F short monorail imaging
catheter. Imaging was performed beginning at a point distal
to the lesion and ending at the aortic ostium using the
motorized pull-back system at 0.5 cm/s. The measurement
was obtained at the same point as the smallest lumen of the
preprocedure. Care was taken to assess the vessel at the same
point during all subsequent imaging by accurately measur-
ing distances from side branches used as landmarks. Calcu-
lations were made by an experienced operator who was
blinded to the patient’s group assignment. Total vessel CSA
and lumen CSA were calculated, and the difference between
these two values was defined as PA. The plaque plus media
cross-sectional area was then divided by vessel CSA to
obtain percent PA. In the stent arm group, stent CSA was
calculated after stenting. In some of the stented lesions,
vessel CSA could not be calculated owing to the artifact of
stent struts. In-stent PA was defined as the difference
between stent CSA and lumen CSA. The increase in PA
during the follow-up period of the stent arm group was
defined as neointima CSA in stent CSA (i.e., the difference
between follow-up in-stent PA and after in-stent PA).
Patient follow-up. In-hospital assessment was performed
for all clinical outcomes including hemorrhagic and vascular
complications, and routine ascertainment of creatine kinase
(CK) and creatine kinase, MB fraction, before treatment,
and 4 to 6 h and 24 h postprocedure. After patient
discharge, clinical follow-up examinations were conducted
on an outpatient basis at least once a month. A clinical
follow-up examination was performed at three and six
months and at one year to assess the occurrence of an
adverse cardiac event (death, myocardial infarction or any
repeat revascularization procedure).
Abbreviations and Acronyms
CSA 5 cross-sectional area
CK 5 creatine kinase
DCA 5 directional coronary atherectomy
DS 5 percent diameter stenosis
IVUS 5 intravascular ultrasound
LAD 5 left anterior descending artery
MLD 5 minimal lumen diameter
NHLBI 5 National Heart, Lung, Blood Institute
PA 5 plaque plus media cross-sectional area
QCA 5 quantitative coronary angiography
TIMI 5 thrombolysis in myocardial infarction
TLR 5 target lesion revascularization
TVR 5 target vessel revascularization
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Angiographic and IVUS follow-up examinations were
performed routinely at three and six months. If target lesion
revascularization (TLR) was performed at three months
owing to restenosis, preprocedural angiography and IVUS
images at three months were used for follow-up QCA and
IVUS analysis of the patient. Revascularization of another
distal lesion located in the same target vessel at the three-
month follow-up examination was defined as target vessel
revascularization (TVR), and the patient was excluded from
angiographic and IVUS analyses even if the target site
showed no evidence of angiographic restenosis until the
six-month follow-up examination.
End points. The prespecified primary angiographic end
point was the six-month angiographic restenosis rate, de-
fined as ^50% DS. Other angiographic assessments in-
cluded initial procedural success (defined as ,50% residual
diameter stenosis in the absence of severe dissections or flow
limitation), and MLD and DS at baseline, after the proce-
dure, and at follow-up.
Clinical end points included short-term procedural safety,
clinical restenosis surrogates and clinical status at one year.
All deaths were considered cardiac-related unless clearly
attributable to a noncardiac cause. Documentation of new
pathologic Q waves in two or more contiguous leads in an
electrocardiogram associated with any elevation of CK-MB
was required for a diagnosis of Q-wave myocardial infarc-
tion. Non-Q-wave myocardial infarction was defined as the
elevation of CK more than twice the upper limit associated
with any elevation of CK-MB without the appearance of Q
waves.
The need for coronary-aorto bypass surgery or use of a
nonrandomized bailout device (stenting in the DCA arm)
was judged as emergent if it was performed for overt or
threatened abrupt closure. Abrupt closure was defined as
reduced coronary flow (Thrombolysis in Myocardial Infarc-
tion [TIMI] trial grade 0 or 1) due to mechanical compli-
cations that led to emergent coronary-aorto bypass surgery
or use of a bailout device or resulted in death, Q-wave
myocardial infarction or non-Q-wave myocardial infarction.
Threatened abrupt closure was diagnosed by the presence of
an National Heart, Lung and Blood Institute (NHLBI)
grade B dissection and ^50% diameter stenosis, or a
dissection of an NHLBI grade C or worse.
Statistical analysis. We expected that the angiographic
restenosis rate would be 30% in the stent arm and 15% in
the DCA arm groups. To achieve statistical significance, 60
patients needed to be randomized to each group; hence, the
planned sample size was 120 patients. All analyses used
intent-to-treat samples. Continuous variables were ex-
pressed as the mean 6 standard deviation. Variable catego-
ries were expressed as frequencies. The Student t test or
nonparametric analysis by the Mann-Whitney U test was
used for numerical comparisons between groups. The chi-
square test or the Fisher exact test was used for comparison
of variable categories expressed as frequencies. Linear re-
gression analysis was performed to examine the correlation
between paired continuous variables. Survival estimates
were computed by use of Kaplan-Meier methods and
compared using the log-rank test. Statview version 4.11 was
used for data analysis. Statistical significance was established
at the p , 0.05 level.
RESULTS
Patient characteristics. Recruitment lasted from October
1995 through March 1997. A total of 909 patients were
screened, resulting in the enrollment of 126 patients. Four
patients were deregistered owing to documentation of su-
perficial calcified plaque .180 degrees as assessed by pre-
procedural IVUS (n 5 3) or the vessel being smaller than
2.8 mm as measured by online QCA (n 5 1). Therefore,
122 patients were randomized after preprocedural assess-
ment, with 62 patients assigned to the stent arm and 60
patients assigned to the DCA arm.
Baseline patient demographic and clinical data are shown
in Table 1. No significant differences between the two
groups with regard to patient characteristics were observed.
The baseline lesion characteristics of the two groups are
shown in Tables 2 and 3. No significant difference in
angiographic lesion characteristics, morphology and prepro-
cedural QCA data were observed between the two groups.
The lesion length of enrolled lesions was longer than that of
other previously designed trials (1,2,9).
Procedure performance. In the stent arm group, multiple
stents were implanted in 11 lesions (18%) and the mean
number of implanted stents was 1.2 6 0.4. Adjunct dilation
using a balloon:artery ratio of 1.10 6 0.11 was performed
with pressure of 15 6 3 atm. In 27% of procedures, a 4-mm
and larger-sized balloon was used.
The DCA was performed using a 7F catheter in 65% of
procedures and 7F graft cutter in the remaining 35% of
procedures. The number cut was 22 6 11, and the maxi-
mum balloon pressure during cutting was 34 6 12 psi.
Table 1. Baseline Patient Characteristics
Stent
(n 5 62)
DCA
(n 5 60) p Value
Male 82% 82% 0.93
Age (yr) 62 6 8 64 6 10 0.18
Prior MI 50% 37% 0.14
Prior CABG 5% 5% 0.96
Angina 83% 80% 0.77
Multivessel disease 55% 60% 0.56
Hypertension 42% 53% 0.21
Diabetes mellitus 29% 22% 0.35
History of smoking 76% 67% 0.26
Hyperlipidemia 44% 58% 0.10
LVEF 57 6 13 59 6 11 0.44
Data presented are percent of patient group. MI 5 myocardial infarction; CABG 5
coronary-aorto bypass graft; LVEF 5 left ventricular ejection fraction.
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Adjunct dilation was performed in 14 lesions (23%) with a
balloon:artery ratio of 1.05 6 0.15.
The DCA arm group required a longer fluoroscopy time
(20.9 6 13.6 vs. 29.9 6 14.8 min; p 5 0.012) and a greater
amount of contrast medium (285 6 95 vs. 402 6 132 ml;
p 5 0.0001) than the stent arm group.
Acute results. Initial procedural success was obtained in all
patients of both arm groups without the use of an un-
planned device. No patient of either arm group had any
major complications (death, Q-wave myocardial infarction,
emergent coronary-aorto bypass surgery) from the proce-
dure throughout the hospital stay. Oozing of the contrast
due to debulking was observed in two patients in the DCA
arm group, and this was treated solely by adjunct dilation.
Hemorrhagic vascular complications without the need of
surgical repair were observed in one patient of the stent arm
group. Non-Q-wave myocardial infarction occurred in two
patients (3.3%) of the DCA arm group and in one (1.6%) of
the stent arm group. No subacute thrombosis was observed
in the stent arm group.
The QCA analysis showed a similar postprocedural
MLD (2.79 6 0.39 vs. 2.90 6 0.38 mm, stent vs. DCA)
and a similar postprocedural DS (14.8 6 10.0% vs. 12.9 6
8.1%) between the two groups (Table 3). Baseline and acute
results of the IVUS measurement are shown in Table 4. The
immediate lumen CSA was also similar between the two
groups (8.1 6 2.2 vs. 8.5 6 1.8 mm2). Postprocedural
percent PA was obtained in all lesions in the DCA arm
group; however, in only 34 lesions of the stent arm group
was this obtained because vessel CSA could not be mea-
sured in the remaining 28 lesions owing to the artifact of
stent struts.
Postprocedural percent PA was significantly higher for
the stent arm group than for the DCA arm group (58.6 6
5.9% vs. 52.4 6 8.2%; p 5 0.0001). The IVUS images,
which adequately represented vessel and lumen CSA at the
procedure (baseline, postprocedure), were available in 34
lesions of the stent arm group and in 57 lesions of the DCA
arm. The mechanisms of lumen enlargement of both devices
are illustrated in Fig. 1. Acute luminal gain (6.7 6 2.3 vs.
6.6 6 2.1 mm2) was identical in both arm groups. However,
the plaque reduction ratio, which accounted for luminal
gain (calculated as the decrease in PA divided by luminal
gain), was significantly smaller for the stent arm than for the
DCA arm group (46.7% vs. 71.6%; p 5 0.0014).
Table 2. Baseline Lesion Characteristics
Stent
(n 5 62)
DCA
(n 5 60)
p
Value
Vessel treated
RCA 53% 48% 0.11
LAD 26% 38%
LCx 21% 10%
LMT 0% 3%
AHA/ACC type
A/B1 42% 33% 0.33
B2/C 58% 67%
Prior restenosis 8% 5% 0.49
Calcified 34% 33% 0.95
Eccentric 77% 75% 0.75
Ostial 6% 17% 0.077
Data presented are percent of patient group. AHA 5 American Heart Association;
ACC 5 American College of Cardiology; LAD 5 left anterior descending coronary
artery; LCx 5 left circumflex coronary artery; LMT 5 left main trunk coronary
artery; RCA 5 right coronary artery.
Table 3. Baseline and Acute Angiographic Results
Stent
(n 5 62)
DCA
(n 5 60)
p
Value
Lesion length (mm) 14.1 6 7.1 12.8 6 5.3 0.48
RD (mm) 3.23 6 0.44 3.29 6 0.38 0.36
Pre-MLD (mm) 1.01 6 0.39 1.03 6 0.37 0.81
Pre-DS (%) 68.4 6 11.4 69.0 6 10.5 0.76
Post-MLD (mm) 2.79 6 0.39 2.90 6 0.38 0.13
Post-DS (%) 14.8 6 10.0 12.9 6 8.1 0.26
Data presented are mean value 6 SD. RD 5 reference diameter; MLD 5 minimal
lumen diameter; DS 5 diameter stenosis; pre 5 before intervention; post 5 after
intervention.
Table 4. Baseline and Acute Results of IVUS Measurement
Stent DCA
p
Value
Pre-vessel CSA
(mm2)
16.1 6 5.5 (61) 16.2 6 4.1 (57) 0.49
Post-vessel CSA
(mm2)
19.9 6 5.7 (34) 18.0 6 3.8 (60) 0.20
Post-lumen CSA
(mm2)
8.1 6 2.2 (62) 8.5 6 1.8 (60) 0.37
Post-percent PA
(%)
58.6 6 5.9 (34) 52.4 6 8.2 (60) 0.0001
Data presented are mean value 6 SD. Data in parentheses indicates number of
eligible lesions for measurement. CSA 5 cross-sectional area; PA 5 plaque plus
media area; pre 5 before intervention; post 5 after intervention.
Figure 1. Difference in mechanism of lumen enlargement by
stenting (n 5 34) and DCA (n 5 57). Both strategies provided an
identical acute luminal gain by plaque reduction and vessel
expansion. However, the plaque reduction ratio, which accounted
for luminal gain, was significantly smaller in the stent arm (46.7%
vs. 71.6%; p 5 0.0014). Striped bars 5 plaque reduction; gray
bars 5 vessel expansion.
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Angiographic follow-up. Three-month follow-up angiog-
raphy could not be performed in two patients: one patient of
the DCA arm group who had no recurrent angina or
exhibition of a ST depression under stress electrocardiog-
raphy rejected undergoing follow-up angiography; and one
patient of the stent arm group, who was implanted with a
single Palmaz-Schatz stent in the mid-left anterior descend-
ing artery (LAD), died suddenly just before the follow-up
angiography. Therefore, three-month follow-up angiogra-
phy was performed in a total of 120 patients (61 in the stent
arm group and 59 in the DCA arm group). The QCA
analysis showed a significantly smaller MLD (1.95 6 0.65
vs. 2.33 6 0.63 mm; p 5 0.001) and a significantly higher
DS (38.0 6 17.7% vs. 27.9 6 16.0%; p 5 0.001) in the stent
arm group. Binary angiographic restenosis rate (23.0% vs.
8.5%; p 5 0.030) was also significantly higher in the stent
arm group.
After three-month follow-up angiography, two patients
in the DCA arm group who escaped target-site restenosis
underwent TVR for another distal lesion located in the
same target vessel. One patient who had DCA for a
proximal LAD lesion and Wiktor stent implantation for a
distal LAD lesion underwent TVR due to in-stent resteno-
sis. Another patient who had DCA for an ostial LAD lesion
and conventional balloon angioplasty for a lesion in the
mid-LAD died due to restenosis in the mid-LAD. There-
fore, six-month follow-up angiography was performed in 61
eligible patients in the stent arm group and 57 eligible
patients in the DCA arm group 232 6 84 days after the
procedure. The final angiographic follow-up rate was 96.7%
(118/122).
Analysis of lumen dynamics until the six-month
follow-up angiography is shown in Table 5, and the results
of follow-up MLD and DS are shown in Figure 2. The
minimal lumen diameter was significantly smaller (1.89 6
0.73 vs. 2.18 6 0.62 mm; p 5 0.023) and DS significantly
higher (40.1 6 19.2% vs. 32.1 6 16.9%; p 5 0.018) in the
stent arm group. Late loss (0.91 6 0.71 vs. 0.71 6 0.52 mm;
p 5 0.075) and loss index (0.52 6 0.43 vs. 0.40 6 0.33 mm;
p 5 0.070) were larger, but not significantly, in the stent
arm group. Angiographic restenosis, the primary end point,
was significantly lower in the DCA arm group (32.8% vs.
15.8%; p 5 0.032).
Follow-up lesion length of restenotic lesions was longer
(14.4 6 6.2 mm vs. 10.1 6 4.4 mm; p 5 0.078) in the stent
arm group. Diffuse restenosis, defined as $15 mm length,
was observed in 36.8% (7/19) of the stent arm group and
11.1% (1/9) of the DCA arm group.
Serial IVUS assessment. Adequate serial IVUS study
(baseline, postprocedural and six-month follow-up) was
obtained in a total of 112 lesions; 56 lesions in each arm
group. The IVUS follow-up rate was 91.8% (112/122). The
decrease in lumen CSA from the procedure to the follow-up
was significantly larger (2.8 6 2.1 vs. 1.5 6 3.0 mm2; p 5
0.0041) in the stent arm group. Thus, follow-up lumen
CSA was significantly smaller (5.3 6 2.8 vs. 7.0 6 3.2 mm2;
Table 5. Analysis of Lumen Dynamics
Stent
(n 5 61)
DCA
(n 5 57)
p
Value
RD (mm) 3.23 6 0.44 3.29 6 0.38 0.48
Pre-MLD (mm) 1.00 6 0.39 1.01 6 0.36 0.92
Post-MLD (mm) 2.80 6 0.39 2.89 6 0.38 0.19
Acute gain (mm) 1.80 6 0.48 1.88 6 0.45 0.32
Post-DS (%) 14.7 6 10.1 12.7 6 8.3 0.25
Follow-up MLD (mm) 1.89 6 0.73 2.18 6 0.62 0.023
Late loss (mm) 0.91 6 0.71 0.71 6 0.52 0.075
Loss index 0.52 6 0.43 0.40 6 0.33 0.070
Follow-up DS (%) 40.1 6 19.2 32.1 6 16.9 0.018
Restenosis rate 32.8% 15.8% 0.032
Data presented are mean value 6 SD. RD 5 reference diameter; MLD 5 minimal
lumen diameter; DS 5 diameter stenosis; pre 5 before intervention; post 5 after
intervention.
Figure 2. Cumulative distribution of minimal lumen diameter
(MLD) (A) and diameter stenosis (B) at preprocedure (Pre),
immediately after the procedure (Post) and at the six-month
angiographic follow-up (F/U). Post-MLD and postdiameter ste-
nosis were almost identical in both groups. However, the DCA
arm showed larger MLD and lower diameter stenosis at F/U, with
significantly lower (15.8% vs. 32.8%; p 5 0.032) binary angio-
graphic restenosis (defined as F/U diameter stenosis ^50%).
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p 5 0.030) in the stent arm group. The mechanism of the
reduction in lumen CSA is illustrated in Figure 3. In the
stent arm group, the stent CSA did not change until almost
follow-up. In the DCA arm group, the change in vessel
CSA was correlated with the change in lumen CSA, as
shown in Figure 4 (r 5 0.695, p , 0.0001). However, it was
bidirectional, and the decrease in vessel CSA was only 0.4 6
2.8 mm2 on the average, as shown in Figure 3. In contrast,
the increase in PA was significantly larger (3.1 6 2.0 vs.
1.1 6 2.6 mm2; p , 0.0001) in the stent arm group, which
mainly accounted for the difference in lumen CSA reduc-
tion between the two devices.
Clinical follow-up. By the first year there had been one
death in the stent arm group (sudden death 90 days after
procedure) resulting in a mortality rate of 1.6%. There were
no deaths in the DCA arm group. The Q-wave myocardial
infarction was not observed in either group. Target lesion
revascularization by one year was required in 18 patients
(29.0%) of the stent arm and in 9 patients (15.0%) of the
DCA arm group; the incidence tended to be slightly lower
in the DCA arm group (p 5 0.062). Coronary-aorto bypass
surgery TVR was performed in two patients in the stent arm
group (3.2%): in one patient owing to refractory instent
restenosis and in one patient because of progression of a left
main trunk lesion. The incidence of TVR was lower in the
DCA arm group (32.3% vs. 18.3%; p 5 0.086), although
not significantly. Target vessel failure, defined as either
death or TVR, also tended to be lower in the DCA arm
group (33.9% vs. 18.3%; p 5 0.056) (Table 6). In the DCA
arm group, the number of percutaneous interventions for TLR
was once for eight patients and twice for another patient.
However, in the stent arm, TLR was required more than twice
in three patients owing to refractory in-stent restenosis (three
times for two patients and four times for one patient).
DISCUSSION
Palmaz-Schatz stents are shown to reduce restenosis rates
compared with balloon angioplasty in simple lesions (1,2).
However, when stent indications are expanded to complex
or small vessels, the efficacy in long-term results is attenu-
ated (3), because the treatment of in-stent restenosis (in
particular diffuse in-stent restenosis) remains unsatisfactory
(14,15). Directional coronary atherectomy was developed as
a way to excise coronary atheroma, providing an alternative
to balloon angioplasty. The first two randomized trials
comparing DCA with balloon angioplasty, in which tissue
resection by DCA was limited, failed to show significant
improvement in early or late clinical and angiographic
outcomes with DCA (4,5). However, recent multicenter
studies have revealed that the “optimal” DCA technique
aimed at larger early lumen diameters could produce better
clinical and angiographic outcomes (6–8).
Our single-center experience showed that DCA proce-
dure was associated with favorable long-term angiographic
results, especially after the introduction of IVUS, and that
the most suitable lesion characteristic for DCA was a
relatively large vessel (16). Therefore, we hypothesized that
Figure 3. Mechanism of late lumen loss after stenting (n 5 56)
and DCA (n 5 56) assessed by serial IVUS examination. Changes
in stent CSA (10.3 mm2) after stenting and vessel CSA (20.4
mm2) after DCA were not remarkable. However, the increase in
PA was significantly larger (3.1 vs. 1.1 mm2; p , 0.0001) in the
stent arm than in the DCA arm, which accounted for the
significantly larger reduction in lumen CSA (2.8 vs. 1.5 mm2; p 5
0.004).
Figure 4. Change in lumen CSA (from postprocedure to follow-
up) correlated with the change in vessel CSA in the DCA arm
group (r 5 0.695, p , 0.0001). However, the change in vessel
CSA was bi-directional.
Table 6. Cumulative One-Year Clinical Outcome
Stent (n 5 62) DCA (n 5 60) p Value
Death 1 (1.6%) 0 0.51
CABG 2 (3.2%) 0 0.26
TLR 18 (29%) 9 (15%) 0.062*
TVR 20 (32.3%) 11 (18.3%) 0.086*
TVF 21 (33.9%) 11 (18.3%) 0.056*
The p values* were detected by log-rank test with Kaplan-Meier methods. Data in
parentheses indicate percent of patients.
TLR 5 target lesion revascularization; TVR 5 target vessel revascularization;
TVF 5 target vessel failure.
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in lesions for which both DCA and stenting can be applied,
optimal atherectomy by “aggressive” DCA using IVUS
would translate into a better long-term angiographic result
than that seen in primary stenting. This study was con-
ducted to compare the angiographic and clinical results
between “aggressive” DCA and primary Palmaz-Schatz
stent implantation. Results of the study indicate that ag-
gressive DCA may provide superior angiographic and clin-
ical outcomes to primary stenting.
Effect of aggressive DCA on angiographic outcomes.
Intravascular ultrasound examination of the target lesion
shows the precise plaque distribution, which enables aggres-
sive tissue resection without increasing procedural compli-
cations such as major perforation. In patients assigned to the
DCA arm group of the present study, tissue resection was
performed, repeatedly if necessary, according to the residual
percent PA. Consequently, a lower postprocedural percent
PA of 52.4% was obtained compared with 57.9% in a
previous optimal DCA study (7). This “aggressive” DCA
strategy produced a similar angiographic postprocedural
MLD (2.90 mm vs. 2.79 mm) and a similar DS (12.9% vs.
14.8%) compared with primary Palmaz-Schatz stent im-
plantation.
However, follow-up angiography showed a larger MLD
(2.18 mm vs. 1.89 mm; p 5 0.023) and a lower %DS (32.1%
vs. 40.1%; p 5 0.018) associated with a lower restenosis rate
(15.8% vs. 32.8%; p 5 0.032) in the DCA arm group than
in the stent arm group. These results indicate that more
favorable long-term angiographic results can be obtained by
aggressive DCA plaque debulking than by primary stenting.
The angiographic restenosis rate (32.8%) and loss index
(0.52) in the stent arm were higher than those obtained in
previous studies (1,2,9). The immediate stent area (8.1
mm2) assessed by IVUS was almost similar to that described
in other IVUS-guided stenting trials (17,18). However, the
lesion length of enrolled lesions in the present study was not
limited, and thus the lesion length of the stent arm
(14.1 mm) was longer than in those previous trials (1,2,9),
and multiple stent implantation to fully cover the lesion was
required in 18% of cases. These differences in baseline
characteristics are believed to attenuate the efficacy of
primary stenting.
Mechanism of restenosis assessed by IVUS. Late lumen
loss after stenting is caused by intimal hyperplasia within the
stent without geometric remodeling (19). In contrast, in
nonstented lesions geometric constrictive remodeling is
considered to be the main mechanism of restenosis (20). In
a previous study we found that patients with DCA exhibited
constrictive remodeling process; however, the predominant
mechanism of restenosis was intimal hyperplasia (21). Serial
IVUS examinations of the present study also revealed that
late lumen loss after aggressive DCA was primarily caused
by intimal hyperplasia (1.1 mm2), and constrictive remod-
eling after aggressive DCA was not significant (0.4 mm2).
Lansky et al. (22) reported that late lumen loss after optimal
DCA correlated more strongly with constrictive remodeling
than with intimal hyperplasia. The present study also
showed a significant correlation between late lumen loss and
geometric remodeling in the DCA group. However, the
geometric remodeling was bi-directional. This difference is
thought to be due to the lower postprocedural percent PA of
52.4% observed in the present study. We consider that
aggressive DCA tends to result in compensatory remodel-
ing. Deep cutting beyond media by aggressive DCA may be
one reason for this positive remodeling (23).
Furthermore, aggressive DCA strategy was associated
with significantly less intimal hyperplasia (1.1 vs. 3.1 mm2;
p , 0.0001) than was primary stenting, and consequently
with significantly less late lumen loss (1.5 vs. 2.8 mm2; p 5
0.0041). The difference in intimal hyperplasia between the
two devices is thought to result partially from the difference
in mechanisms of lumen enlargement. Plaque reduction
mainly accounted for the luminal gain after DCA (72%),
whereas approximately 50% of the gain by stenting was due
to an increase in vessel area. These results suggest that vessel
expansion by stenting may accelerate smooth muscle cell
proliferation induced by expanding or lacerating the media
or the adventitia (24).
Clinical benefit of aggressive DCA. Although not statis-
tically different, the TLR and TVR rates at one year were
higher in the stent arm group (29.0% vs. 15.0%; p 5 0.062
in TLR, 32.3% vs. 18.3%; p 5 0.086 in TVR) than in the
DCA arm group. Target vessel failure also tended to be
higher in the stent arm (33.9% vs. 18.3%; p 5 0.056). These
clinical results were consistent with the angiographic
follow-up results. Furthermore, it should be noted that
stenting always carries the risk of refractory in-stent resteno-
sis, which requires frequent TLR or other revascularization
strategies such as coronary-aorto bypass surgery. In the
present study, repeated TLR or coronary-aorto bypass
surgery was required in four patients (6.5%) of the stent arm
group due to refractory in-stent restenosis. In contrast,
patients who demonstrated clinical restenosis in the DCA
arm group needed percutaneous TLR only once, or at the
most twice. Because a consensus concerning the treatment
of refractory in-stent restenosis has not been established, we
believe aggressive atherectomy to be more effective in
long-term clinical outcomes than primary stenting.
Study limitations. Although this was a prospective ran-
domized study, only 122 patients and only a single center
were involved. In contrast to stenting, DCA is a demanding
technique. Aggressive DCA can never be performed with-
out IVUS; it requires repeated IVUS examination during
the procedure, and it carries the risk of perforations.
Furthermore, DCA involves specific procedural techniques,
such as the precise evaluation of plaque distribution by
IVUS, and the appropriate control of atherocatheters. Con-
sequently, this strategy needs longer procedural and fluoro-
scopic times as well as in-depth training of operators. Only
Palmaz-Schatz stents were used with high-pressure postdi-
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lation technique in the present study. Other longer types of
stents are now available; these reduce the need for multiple
stent placement. High-pressure postdilations are used less
frequently than before. Therefore, these differences may
conceivably alter the incidence of restenosis observed after
stenting.
Conclusions. This study suggests that “aggressive” DCA
strategy may provide superior angiographic and clinical
outcomes compared with primary stent implantation. Thus,
from the viewpoint of long-term outcome, we believe
aggressive DCA should be used as an alternative to primary
stenting if DCA can be applied.
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